Entrada Therapeutics, Inc. (TRDA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Entrada Therapeutics, Inc. reported revenue of $25.42M, down 87.9% from the prior year. The company ran a net loss, with a net margin of -565.5%. It held $377.38M in total assets against $71.25M in total liabilities.
Key ratios (FY2025)
-621.1%
Operating margin
-565.5%
Net margin
-47.0%
Return on equity
-87.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $25.42M | $210.78M | $129.01M | — | — | — | — |
| Operating Income | -$157.90M | $47.01M | -$3.16M | -$97.25M | -$51.13M | -$26.67M | — |
| Net Income | -$143.75M | $65.63M | -$6.68M | -$94.62M | -$51.16M | -$26.52M | — |
| EPS (Diluted) | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 | $-24.00 | — |
| Total Assets | $377.38M | $526.32M | $469.19M | $252.06M | $305.83M | $43.53M | — |
| Total Liabilities | $71.25M | $97.64M | $226.83M | $39.50M | $7.12M | $3.36M | — |
| Shareholders' Equity | $306.13M | $428.68M | $242.36M | $212.55M | $298.72M | -$41.49M | -$15.52M |
| Cash & Equivalents | $90.39M | $101.21M | $67.60M | $45.16M | $291.06M | $39.05M | — |
| Operating Cash Flow | -$128.51M | -$41.56M | $139.80M | -$93.79M | -$50.86M | -$25.57M | — |
| Capital Expenditures | $1.04M | $3.16M | $5.61M | $2.89M | $4.58M | $2.32M | — |
| Shares Outstanding | 38.28M | 37.57M | 33.44M | 31.39M | 31.22M | 1.24M | — |